DGAT1 Inhibitor Composition for Opioid-Induced Constipation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for opioid-induced constipation (OIC) are often ineffective and associated with significant side effects, including bowel obstruction, electrolyte abnormalities, and severe stomach pain, highlighting the need for a more effective and side-effect-minimized treatment.
Innovation Solution
Administering a therapeutically effective amount of a DGAT1 inhibitor, such as pradigastat or compound 9, to reduce gastrointestinal dysfunction symptoms, including OIC, by targeting the diacylglycerol O-acyltransferase 1 enzyme involved in triglyceride biosynthesis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If bulk-forming laxatives (e.g., psyllium, methylcellulose) and excessive dietary fiber intake are used to treat constipation, then bowel movement frequency may increase, but bowel obstruction and fecal impaction are caused
Solution Approach 1:
The patent changes the therapeutic approach from bulk-forming agents to DGAT1 inhibitors, fundamentally altering the mechanism of action. DGAT1 inhibitors modify lipid metabolism parameters in the gut, specifically reducing diacylglycerol acyltransferase 1 activity, which decreases triglyceride synthesis and alters stool composition without causing obstruction. This parameter change in the biochemical pathway resolves the contradiction by achieving bowel movement improvement through a different physiological mechanism.
2Speed
If stimulants are used to treat constipation, then bowel propulsion is enhanced, but bowel irritation occurs due to propulsion of overly dry fecal material
Solution Approach 1:
The patent shifts from stimulating bowel motility to modifying stool composition through DGAT1 inhibition. By changing the lipid content and water-binding properties of fecal material through enzyme inhibition, the stool becomes softer and easier to pass without requiring aggressive propulsion. This resolves the contradiction by improving bowel movement through compositional change rather than mechanical stimulation.
3Ease of operation
If mineral oil is used to treat constipation, then stool softening occurs, but absorption of fat-soluble vitamins A, D, E, and K decreases with prolonged use
Solution Approach 1:
The patent introduces DGAT1 inhibitors as an intermediary mechanism that naturally regulates lipid metabolism in the gut. Instead of using mineral oil as an external lubricant that interferes with vitamin absorption, the DGAT1 inhibitor acts as a mediator that modulates endogenous lipid synthesis. This produces stool softening effects through biochemical regulation of triglyceride formation, eliminating the need for mineral oil and preventing vitamin loss.
4Productivity
If osmotics are used to treat OIC, then bowel movement is stimulated, but electrolyte abnormalities occur and rectal administration is required
Solution Approach 1:
The patent changes the therapeutic mechanism from osmotic stimulation to enzymatic inhibition. DGAT1 inhibitors modify the biochemical composition of intestinal contents by reducing triglyceride synthesis, which naturally promotes bowel movements through altered stool consistency and volume. This parameter change in lipid metabolism avoids the electrolyte disturbances associated with osmotic laxatives and allows for safer oral administration.
5Productivity
If Methylnaltrexone (Relistor) is administered by subcutaneous injection to treat OIC, then constipation symptoms are reduced, but severe stomach pain is caused
Solution Approach 1:
The patent replaces the mechanical injection route with oral administration of DGAT1 inhibitors. By substituting the delivery mechanism from parenteral (injection) to enteral (oral), the patent eliminates the severe stomach pain associated with Methylnaltrexone while maintaining therapeutic effectiveness. The DGAT1 inhibitor works through a different biochemical pathway that does not provoke gastrointestinal distress.
Data Source
AI summary
The present disclosure provides methods related to treating or preventing gastrointestinal dysfunction in a subject in need thereof, which include the use of a diacylglycerol O-acyltransferase 1 (DGAT1) inhibitor. The disclosure also provides pharmaceutical compositions comprising a DGAT1 inhibitor, or pharmaceutically acceptable salts or esters thereof, useful for the treatments described herein.